Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of four new Droplet Digital™ PCR (ddPCR™) ...
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that in two studies ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) a global leader in life science research and clinical diagnostics products, today announced a collaboration agreement with Oncocyte Corporation (Nasdaq ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), provides an overview of advances supporting the Company’s overall corporate strategy to improve science and healthcare in the year to date. Centered ...
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its SARS-CoV-2 ...
Hercules, CA -- October 19, 2015 -- Bio-Rad's Droplet Digital PCR (ddPCR™) technology identifies viral RNA mutations in clinical samples with greater precision, sensitivity, and reproducibility than ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced today that the company’s management will host an informational ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of the ddPCR™ Supermix for Residual DNA Quantification. When used with Bio-Rad’s Droplet Digital™ PCR Systems, this supermix ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback